

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2021/226163 A3

(43) International Publication Date
11 November 2021 (11.11.2021)

(51) International Patent Classification:

A61K 39/395 (2006.01) *C07K 16/28* (2006.01)
C07K 16/00 (2006.01) *C07K 16/30* (2006.01)
G01N 33/53 (2006.01) *C07K 47/48* (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2021/030773

(22) International Filing Date:

05 May 2021 (05.05.2021)

(88) Date of publication of the international search report:

16 December 2021 (16.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/020,806 06 May 2020 (06.05.2020) US

(71) Applicant: **DRAGONFLY THERAPEUTICS, INC.**
[US/US]; 35 Gatehouse Drive, Waltham, MA 02451 (US).

(72) Inventors: **BARUAH, Hemanta**; 2513 Navarro Trail, Euless, TX 76039 (US). **CHANG, Gregory, P.**; 143 Saunders Street, Medford, MA 02155 (US). **CHEUNG, Ann, F.**; 25 Morningside Lane, Lincoln, MA 01773 (US). **GRINBERG, Asya**; 37 Follen Road, Lexington, MA 02421 (US).

(74) Agent: **MARTINEK, Sebastian** et al.; Jones Day, 250 Vesey Street, New York, NY 10281 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTIBODIES TARGETING CLEC12A AND USE THEREOF

(57) Abstract: Disclosed are proteins with antibody heavy chain and light chain variable domains that can be paired to form an antigen-binding site targeting CLEC12A on a cell, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer.



WO 2021/226163 A3